Neuroscience Antibodies Market worth $4.18 Billion by 2023
According to research report the Neuroscience Antibodies Market is expected to reach USD 4.18 Billion by 2023 from USD 2.57 Billion in 2018, at a CAGR of 10.2%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=129888612
Growth
in this market is driven by the rising incidence of neurological
diseases, increasing investments in neuroscience research, and growth in
the pharmaceutical and biotechnology industries. On the other hand,
quality and cost concerns over the production of antibodies are the
major factor restraining the growth of this market.
The Neuroscience Antibodies Market are segmented based on product, technology, application, end user, and region.
Based
on product, the neuroscience antibodies market is segmented into
consumables and instruments. The consumables segment is expected to
account for the largest market share in 2018 and is projected to
register the highest CAGR during the forecast period. The consistent
usage of consumables and their frequent purchases, and rising government
initiatives in the genomics and proteomics research sector are the
major factors supporting the growth of the consumables segment.
Based
on technology, the neuroscience antibodies market is segmented into
immunoassays/immunochemistry, molecular diagnostics, clinical chemistry,
and other technologies. In 2018, immunoassays/immunochemistry segment
is expected to account for the largest share of the neuroscience
antibodies and assays market. The large share of this segment is
attributed to the development of novel antibodies and assays for
immunoassay techniques, technological developments in immunoassays, and
rising government initiatives in the genomics and proteomics research
sector.
Based on application, the neuroscience antibodies and
assays market is segmented into research, drug discovery and
development, and in vitro diagnostics. The in vitro diagnostics
applications segment is expected to register the highest CAGR during the
forecast period. The high growth of this segment is attributed to the
increasing incidence and prevalence of neurological diseases across the
globe, especially in developing countries.
In 2018, North America
is expected to dominate the market followed by Europe. The large share
of this geographical segment is attributed to the increasing investments
for the development of structure-based drug designs, growing research
in the field of genomics and proteomics, rising demand for high-quality
research tools for data reproducibility, and the focus of stakeholders
on research projects involving proteins, associated biomolecules, and
genes.
Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=129888612
The neuroscience antibodies market
is fragmented, with the presence of several large as well as emerging
players. In 2017, Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad
(US), and Merck KGaA (Germany) were the leading players in the
neuroscience antibodies market. Other major players include BioLegend
(US), Cell Signaling Technology (US), F. Hoffmann-La Roche
(Switzerland), GenScript (China), Rockland Immunochemicals (US), Santa
Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland).
Comments
Post a Comment